Investigating DNA damage mechanisms and treatments for Parkinson's disease
Novel DNA damage-Based Mechanisms and Therapeutics for Parkinson’s disease
This study is looking at how damage to DNA in brain cells might affect the progression of Parkinson's disease, using a special mouse model to see if this damage causes the disease or happens because of it, with hopes of finding new ways to help slow down or stop the disease.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-10508019 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of DNA damage, specifically double-strand breaks, in the progression of Parkinson's disease (PD). By using a novel mouse model, the study aims to determine whether these DNA damages are a primary cause of PD or simply a consequence of the disease. The researchers will explore how these DNA damages contribute to neuronal loss and behavioral deficits associated with PD. This investigation could lead to new therapeutic strategies aimed at repairing DNA damage to slow or halt the progression of the disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease or those at risk of developing the condition.
Not a fit: Patients with Parkinson's disease who are already in advanced stages of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that slow or stop the progression of Parkinson's disease.
How similar studies have performed: While the role of DNA damage in neurodegenerative diseases has been studied, this specific approach to understanding its impact on Parkinson's disease is relatively novel.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Khan, Mohammad Moshahid — University of Tennessee Health Sci Ctr
- Study coordinator: Khan, Mohammad Moshahid
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.